Valeant's newly expanded Relistor franchise draws interest from potential buyers

Rumors have been flying about which assets Valeant may sell off as it looks to drum up money to pay down its massive debt pile. And now, word has it that Relistor could be one of them.

The constipation therapy has drawn interest from potential buyers, Bloomberg reports, though it’s unclear whether Valeant ($VRX) actually intends to sell it. Doing so could bring in between $400 million and $500 million, the news service notes.

Valeant has been counting on Relistor to help it challenge rival AstraZeneca ($AZN) in the opioid-induced constipation arena, and last month the Canadian drugmaker’s product got a competitive boost. The FDA approved an oral formulation of the therapy, erasing AZ’s edge with its own pill, Movantik.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Analysts still aren’t necessarily sure Relistor can bring in the blockbuster revenues Salix has predicted, though. Evercore ISI’s Umer Raffat, for one, said in July that he’s modeling about $250 million in peak sales for the entire franchise.

Relistor isn’t the only member of Valeant’s portfolio that’s potentially on the block. CEO Joseph Papa has spoken out the benefit about potential divestments, adding that in addition to raising funds, jettisoning products could also help reduce the complexity of the company’s business--an important step as it looks to improve financial transparency. So far, reports have listed Egyptian drugmaker Amoun, 2013 skincare buy Obagi Medical Products, laggard cancer vaccine Provenge and other assets as potentially up for grabs.

Meanwhile, the embattled company--which has faced pricing pushback, channel-stuffing allegations and other hurdles in addition to its debt problems--said Monday that it would be shaking up its top ranks. The company has brought on a new EVP and general counsel and an SVP of business strategy and communications, and its expanded the roles of some of its top execs, too. 

- get more from Bloomberg
- read Valeant's release

Special Report: The most influential people in biopharma today - 2016 - J. Michael Pearson - Valeant

Related Articles:
Valeant's Relistor a future blockbuster? With AZ in the game, analysts aren't buying it
Valeant considers putting Egypt's Amoun up for grabs: Bloomberg
Embattled Valeant doesn't 'need to sell anything,' new CEO says
Valeant weighs sales of controversial heart meds, laggard Provenge: Bloomberg
Valeant looks at what it might sell to raise cash: Reuters
Valeant investors, shocked by lightweight guidance, aren't buying CEO Pearson's recovery plans
Could a Bausch & Lomb IPO help save debt-laden Valeant? Ackman thinks so
Valeant posts 36% growth amid pricing scrutiny; may sell neurology biz

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.